Vabysmo improved vision in Japanese patients with angioid streaks

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) announced that results from the Phase III clinical trial (NIHONBASHI study) of anti-VEGF/anti-Ang-2 bispecific antibody Vabysmo (faricimab) intravitreal injection 120mg/mL, for angioid streaks associated with neovascularization were presented at the 129th Annual Meeting of the Japanese Ophthalmological Society on April 17.

“Based on the study results, Vabysmo is expected to become the first drug for angioid streaks, for which there are currently no approved drugs in Japan. The regulatory approval review is currently underway under priority review. Chugai will make every effort to obtain approval in Japan so that we can deliver this drug to patients who are eagerly awaiting treatment as soon as possible,” said Dr Osamu Okuda, president and chief executive of Chugai, which s majority owned by Swiss pharma giant Roche (ROG: SIX).

Chugai files for Japanese approval of Vabysmo for the treatment of angioid streaks associated with neovascularization in September last year.